TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02346955

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CM-24 (MK-6018)
Description: humanized IgG4 (kappa) isotype monoclonal antibody against CEACAM1 by intravenous (IV) infusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CM-24 (MK-6018)
Description: humanized IgG4 (kappa) isotype monoclonal antibody against CEACAM1 by intravenous (IV) infusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CM-24 (MK-6018)
Description: humanized IgG4 (kappa) isotype monoclonal antibody against CEACAM1 by intravenous (IV) infusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CM-24 (MK-6018)
Description: humanized IgG4 (kappa) isotype monoclonal antibody against CEACAM1 by intravenous (IV) infusion
Study: NCT00569166

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Paced breathing (15 min twice daily, 6 breaths/min)
Description: Patients practice paced breathing for 15 minutes twice daily, 6 breaths/min, 5-7 days weekly, following an instructional CD, for 8 weeks.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Paced breathing (10 min once daily, 14 breaths/min)
Description: Patients practice paced breathing for 10 minutes once daily, 14 breaths /min, 5-7 days weekly, following an instructional CD, for 8 weeks.
Study: NCT00532350

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: QAT370
Study: NCT02346955

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CM-24 (MK-6018)
Description: humanized IgG4 (kappa) isotype monoclonal antibody against CEACAM1 by intravenous (IV) infusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CM-24 (MK-6018)
Description: humanized IgG4 (kappa) isotype monoclonal antibody against CEACAM1 by intravenous (IV) infusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CM-24 (MK-6018)
Description: humanized IgG4 (kappa) isotype monoclonal antibody against CEACAM1 by intravenous (IV) infusion
Study: NCT00532350

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tiotropium
Study: NCT01041443

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT02346955

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CM-24 (MK-6018)
Description: humanized IgG4 (kappa) isotype monoclonal antibody against CEACAM1 by intravenous (IV) infusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CM-24 (MK-6018)
Description: humanized IgG4 (kappa) isotype monoclonal antibody against CEACAM1 by intravenous (IV) infusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab (MK-3475)
Description: 200 mg of Pembrolizumab by IV infusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab (MK-3475)
Description: 200 mg of Pembrolizumab by IV infusion
Study: NCT01058018

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RVX000222
Description: RVX000222 twice a day for 12 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RVX000222
Description: RVX000222 twice a day for 12 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RVX000222
Description: RVX000222 twice a day for 12 weeks
Study: NCT02346955

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab (MK-3475)
Description: 200 mg of Pembrolizumab by IV infusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab (MK-3475)
Description: 200 mg of Pembrolizumab by IV infusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab (MK-3475)
Description: 200 mg of Pembrolizumab by IV infusion
Study: NCT02685839

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intelligent POWER Rehabilitation Cluster Machine

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: general physical therapy
Study: NCT01041443

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: reverse transcriptase-polymerase chain reaction
Description: Correlative studies

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: DNA methylation analysis
Description: Correlative studies
Study: NCT04275609

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: AI generated report
Description: After the endoscopic procedure, the physicians click the structured reporting button of computer to automatically complete the report through the structured diagnostic report generation system. The physicians only make minor corrections to the report.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: physicians writing report
Description: After the endoscopic procedure, the physicians writing the report in computer according the procedure.
Study: NCT03035773

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Care Plan Only
Description: Patient participants randomized to Arm A will be sent a copy of the SCP within 3 months of completion of treatment and a copy will be added to their medical record. A copy of the SCP will also be sent to the PCP on record. The SCP will be completed by a nurse, nurse practitioner, or physician assistant. The SCP will be accompanied by a cover letter that will be signed by a member of the clinical team.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Care Plan During a Visit
Description: Patient participants randomized to Arm B will receive a copy of the SCP during an in-person 'stethoscope free' visit with a nurse, nurse practitioner, or physician assistant. A copy of the SCP will be added to the medical record and a copy will be sent to the primary care provider on record. The visit will be scheduled after consent is signed and will occur between 1 and 3 months after completion of treatment. The visit will focus on review of the SCP content and offer an opportunity for patients to ask questions about any aspect of the plan or associated treatment and survivorship issues.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Care Plan During a Visit with an Additional Visit
Description: Participants randomized to Arm C will receive a copy of the SCP during an in-person 'stethoscope free' visit with a nurse, nurse practitioner, or physician assistant. A copy of the SCP will be added to the medical record and a copy will be sent to the primary care provider. The visit will be scheduled after consent is signed and will occur between 1-3 months after completion of treatment. The initial visit will focus on review of the SCP content and offer an opportunity for patients to ask questions about any aspect of the plan or associated treatment and survivorship issues. Patients will also receive a follow up survivorship visit 7-10 months after the end of treatment that will focus on a review of the SCP and offer the opportunity to ask about any persistent or emerging issues.
Study: NCT01058018

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo twice a day for 12 weeks
Study: NCT01157208

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Diet A
Description: Subjects receive dietary counseling, food for two meals and two snacks daily, and access to a website with recipes, approved food lists, and dining out guides for a 12-week intervention.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Diet B
Description: Over a 12-week intervention, subjects receive dietary counseling, food for two meals and two snacks daily, and access to a website with recipes, approved food lists, and dining out guides.
Study: NCT03578484

Intervention type: DIAGNOSTIC_TEST
Intervention: Aesthetic assessment 3D breast scanning
Description: Vectra TM - Canfield Inc breast scan. 3D digital photography scan.
Study: NCT02708394

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: olanzapine
Description: atypical antipsychotic

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo control
Study: NCT00927706

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Assistive technology updating and tune up intervention
Description: This intervention includes 4 components: 1) an in-residence assessment of the mobility preferences of the older person and his/her caregiver; 2) a detailed review of forms of assistance, technological and human, that are currently being used; 3) recommendations by an occupational therapist for possible changes in the older person's mobility assistive technology or assistance strategy; and 4) therapist negotiation of an mobility assistive technology updating and tune-up intervention plan with the individual and his or her caregiver.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Assistive technology updating and tune up intervention
Description: This intervention includes 4 components: 1) an in-residence assessment of the mobility preferences of the older person and his/her caregiver; 2) a detailed review of forms of assistance, technological and human, that are currently being used; 3) recommendations by an occupational therapist for possible changes in the older person's mobility assistive technology or assistance strategy; and 4) therapist negotiation of an mobility assistive technology updating and tune-up intervention plan with the individual and his or her caregiver.
Study: NCT01582321

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Typhoid vaccine
Description: The typhoid vaccine is composed of purified polysaccharide from S. typhi capsule 25 micrograms contained in 0.5 ml solution

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Typhoid vaccine
Description: The typhoid vaccine is composed of purified polysaccharide from S. typhi capsule 25 micrograms contained in 0.5 ml solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cantharidin
Description: 0.1% cantharidin solution in acetone from 0.7% stock solution of cantharone is prepared and applied immediately. 10 μl of cantharidin per disc.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cantharidin
Description: 0.1% cantharidin solution in acetone from 0.7% stock solution of cantharone is prepared and applied immediately. 10 μl of cantharidin per disc.
Study: NCT04039646

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: ERAS treatment
Description: The ERAS group had an enhanced postoperative recovery protocol. The gastric content was aspirated via the nasogastric tube by the anesthesiologist at the end of the procedure, and the nasogastric tube was withdrawn in the operating room immediately after the patient had recovered from anesthesia. and also early feeding and move.

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: ERAS treatment
Description: The ERAS group had an enhanced postoperative recovery protocol. The gastric content was aspirated via the nasogastric tube by the anesthesiologist at the end of the procedure, and the nasogastric tube was withdrawn in the operating room immediately after the patient had recovered from anesthesia. and also early feeding and move.
Study: NCT02182609

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Kit for the Preparation of 99mTc-rhAnnexin V-128
Description: Kit for the Preparation of Tc-99m Recombinant Human Annexin V-128 for Injection
Study: NCT03254277

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 3BNC117-LS
Description: Intravenous infusion of 3BNC117-LS

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 3BNC117-LS
Description: Intravenous infusion of 3BNC117-LS
Study: NCT00599196

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rotigotine
Description: Rotigotine trans-dermal patches, once daily:~10 cm2 (2 mg/24 hours); 20 cm2 (4 mg/24 hours); 30 cm2 (6 mg/24 hours); 40 cm2 (8 mg/24 hours); 50 cm2 (10 mg/24 hours); 60 cm2 (12 mg/24 hours); 70 cm2 (14 mg/24 hours); 80 cm2 (16 mg/24 hours);~Optimal dosing:~During the first year: The maximum Rotigotine dose allowed is 8 mg/24 hours.~After the first year: allowed dose increase of rotigotine up to a maximum of 16 mg/24 hours.
Study: NCT01784809

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Multimedia WORTH
Description: The Multimedia WORTH intervention features the same core elements as the original version, but these core elements are translated into interactive tools and culturally tailored video vignettes designed to enhance group learning and individualized feedback. Participants will interact with Multimedia WORTH at two levels: (1) group materials will be delivered via computer projection onto a screen and (2) participants will complete individual activities and create journal logs tracking their progress on personalized goals on their personal user accounts using laptop computers. The computer multimedia support tool includes text, imagery, animations, audio and video in a format that guide the facilitator's delivery of the intervention. \*\*\*To view pilot features of the Multimedia WORTH intervention in development, please visit the following web address:~http://ccnmtl.columbia.edu/projects/worth/presentation

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Traditional WORTH
Description: The basic format of each WORTH session remains consistent following a sequence of 5 steps: (1) an opening (quote, song, poem) which will provide a brief culturally relevant point of inspiration to engage participants (2) Check-in to review material from the previous session, and to discuss any incidents where participants engaged in risk behaviors and to acknowledge positive ways in which women used new skills to avoid HIV risk; (3) a discussion to raise awareness of links between IPV, drug-related activities, and HIV risks; (4) a skills-building component relevant to the discussion; and (5) review and update participant needs, homework assigned for skills-building at home, and a closing ritual. The WORTH intervention consists of four 2-hour group sessions that are led by a female facilitator.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Wellness Promotion
Study: NCT03254277

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 3BNC117-LS
Description: Intravenous infusion of 3BNC117-LS

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 3BNC117-LS
Description: Intravenous infusion of 3BNC117-LS

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 3BNC117-LS
Description: Intravenous infusion of 3BNC117-LS

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 3BNC117-LS
Description: Intravenous infusion of 3BNC117-LS

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 3BNC117-LS
Description: Intravenous infusion of 3BNC117-LS

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 3BNC117-LS
Description: Intravenous infusion of 3BNC117-LS

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 3BNC117-LS
Description: Intravenous infusion of 3BNC117-LS

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo
Study: NCT01928823

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CBT
Description: 12 sessions of CBT (cognitive behavioral therapy) with psychoeducation and in-vivo exposure

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: CBT
Description: 12 sessions of CBT (cognitive behavioral therapy) with psychoeducation and in-vivo exposure

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: D-Cycloserine
Description: Administered for three times (50mg, oral) directly after exposure
Study: NCT02916407

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sevoflurane
Description: Intravenous ketamine will administrate to the patients for decreasing of separation anxiety of children.~General anesthesia will maintained with sevoflurane 2-3 vol%.
Study: NCT03414723

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ramipril
Description: Pharmaceutical form: tablets~Route of administration: oral
Study: NCT02916407

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Desflurane
Description: Intravenous ketamine will administrate to the patients for decreasing of separation anxiety of children.~General anesthesia will maintained with desflurane 6-7vol%.
Study: NCT01697228

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Vitamin D
Study: NCT01439074

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Mepilex Ag
Description: Dressing

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Silver Sulphadiazine Ag cream
Description: A cream used on burnt areas.
Study: NCT02834923

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Enhanced Engagement Protocol for CTH (EE-CTH)
Description: EE-CTH integrates CTH with an efficacious, structured, motivational interview (MI)-informed protocol.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Connection to Health (CTH)
Description: CTH is a comprehensive SMS program that focuses on behavior change.
Study: NCT00953680

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: losartan potassium (+) hydrochlorothiazide (HCTZ)
Description: Single dose losartan 100 mg/HCTZ 12.5 mg combination tablet in one of two treatment periods.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: losartan potassium
Description: Single dose losartan 100 mg tablet in one of two treatment periods.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: hydrochlorothiazide (HCTZ)
Description: Single dose HCTZ 12.5 mg capsule in one of two treatment periods.
Study: NCT02193087

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TDV Liquid Formulation 1
Description: TDV Liquid Formulation 1 for subcutaneous injection

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TDV Liquid Formulation 1
Description: TDV Liquid Formulation 1 for subcutaneous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TDV Liquid Formulation 2
Description: TDV Liquid Formulation 2 for subcutaneous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TDV IDT Lyophilized
Description: TDV Lyophilized Formulation for subcutaneous injection
Study: NCT01087710

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: medical food with EPA and GLA, vitamins and minerals
Description: 1 8oz serving per day for 12 weeks

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: medical food minus EPA and GLA, antioxidant vitamins/minerals
Description: 1 8oz serving a day for 12 weeks
Study: NCT01929291

Intervention type: BIOLOGICAL
Intervention: Boostrix
Description: Single intramuscular injection

Intervention type: OTHER
Intervention: Safety data collection
Description: Safety monitoring: recording of adverse events using diary cards and recording of serious adverse events using the latest version of Korea's Post-Marketing Surveillance Serious Adverse Event Reporting Form
Study: NCT03311880

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive remediation
Description: Participants will be taught compensatory strategies for subjective cognitive impairment in addition to learning about lifestyle modifications that are known to be beneficial on cognition.
Study: NCT02193087

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: TDV liquid formulation placebo-matching solution for subcutaneous injection
Study: NCT01596686

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: one of two possible colon preparation regimens
Description: Patients are randomized to receive one of the two different preparation regimens for colonoscopy usually employed in our unit, polyethylene glycol or sodium picosulphate and magnesium citrate

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: one of two possible colon preparation regimens
Description: Patients are randomized to receive one of the two different preparation regimens for colonoscopy usually employed in our unit, polyethylene glycol or sodium picosulphate and magnesium citrate
Study: NCT04518709

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Posterior Mitral Annulus Elevation Technique
Description: Posterior mitral annulus elevation technique is performed using a large pledget and non-absorbable braided suture starting from the subvalvular section of the posterior mitral valve sutured to the ring annuloplasty (if in the process of repairing the mitral valve, ring implantation is performed; if without the use of ring annuloplasty, the suture is placed in the left atrial wall / supravalvular of PML), so that the posterior annulus is slightly attracted upward toward the cranial and the PML moves toward the center.

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Conventional Mitral Valve Repair
Description: Conventional mitral valve repair in the pediatric patient using annuloplasty, leaflet resection and plication, sliding-plasty of chordae technique
Study: NCT00669474

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Suction curettage
Description: Suction curettage

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Treatment with Botox
Description: Treatment with Botox
Study: NCT02431442

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: RM-493

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: RM-493

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: RM-493

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: RM-493

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: RM-493

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: RM-493

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT03004989

Intervention type: BEHAVIORAL
Intervention: Programme
Description: The participants of this study had participated in one of three different RTW-GPs. These programmes are designed to enable participants to proactively take action in their daily lives and in collaboration with employers achieve the best possible working conditions. All the group sessions are based on cognitive theory where attention, awareness and reflection on one's own work and life situation is important

Intervention type: BEHAVIORAL
Intervention: Programme
Description: The participants of this study had participated in one of three different RTW-GPs. These programmes are designed to enable participants to proactively take action in their daily lives and in collaboration with employers achieve the best possible working conditions. All the group sessions are based on cognitive theory where attention, awareness and reflection on one's own work and life situation is important
Study: NCT04283565

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Systematic screening of AOMI by BPI measurement.
Description: The strategies will be associated according to a 2\*2 factorial design in order to obtain 4 arms

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Systematic screening of AOMI by BPI measurement.
Description: The strategies will be associated according to a 2\*2 factorial design in order to obtain 4 arms